Larimar Therapeutics, Inc. 8-K

What Happened

• Larimar Therapeutics, Inc. announced its financial results and operational highlights for the quarter ended March 31, 2026 in a press release dated May 14, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K. On the same date Larimar posted an updated corporate slide presentation (Exhibit 99.2) on its website for use in investor and analyst meetings. The Form 8-K was signed by President and CEO Carole S. Ben‑Maimon, M.D.

Key Details

• Filing date: May 14, 2026; quarter covered: Q1 2026 (ended March 31, 2026).
• Press release announcing results: furnished as Exhibit 99.1 to the Form 8-K.
• Updated corporate presentation: posted May 14, 2026 and included as Exhibit 99.2.
• Form 8-K items reported include the results of operations/financial condition disclosure and an “other events” update (investor presentation).

Why It Matters

• This is a routine quarterly disclosure that provides investors with Larimar’s latest quarterly results and the company’s updated investor presentation. Retail investors should review the press release and slides (Exhibits 99.1 and 99.2) to see the actual earnings, revenue, cash position, operational highlights and any clinical or business updates disclosed. The filing does not, by itself, announce executive changes, mergers, or other major corporate events.